🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs
755

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 755 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Page 6 of 16

  1. ALN-ANG3

    Regeneron UK Limited

    Diabetic Kidney Disease (DKD)

    phase 2 small molecule active

    1 trial

  2. ALN-CIDEB

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 2 small molecule active

    1 trial

  3. ALN-HSD

    Regeneron UK Limited

    Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

    phase 2 small molecule active

    1 trial

  4. ALN-KHK

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule terminated

    1 trial

  5. ALN-PNP

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    phase 2 small molecule active

    1 trial

  6. AMG 133, Placebo for AMG 133

    Amgen

    Overweight and Obesity

    phase 2 small molecule active

    1 trial

  7. ARD-101

    Ark Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial

  8. ARO-ALK7

    Arrowhead Pharmaceuticals Ireland Limited

    Obesity

    phase 2 small molecule active

    1 trial

  9. ARO-INHBE

    Arrowhead Pharmaceuticals Ireland Limited

    Obesity

    phase 2 small molecule active

    1 trial

  10. ASC30 tablets

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T2DM (Type 2 Diabetes Mellitus)

    phase 2 small molecule active

    1 trial

  11. AT-1501

    Eledon Pharmaceuticals

    Type 1 Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  12. AT-1501 IV Infusion

    Eledon Pharmaceuticals

    Brittle Type 1 Diabetes Mellitus

    phase 2 mab terminated

    1 trial

  13. AZD5004, AZD5004, AZD5004, Rybelsus 14 mg tablets, Placebo to match AZD5004 (PTM) film-coated tablets, Rybelsus 7 mg tablets, Rybelsus 3 mg tablets

    AstraZeneca AB

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  14. AZD5004, Placebo to match AZD5004 film coated tablet, AZD5004, AZD5004

    AstraZeneca AB

    Participants living with Obesity or Overweight with at least 1 comorbidity

    phase 2 small molecule active

    1 trial

  15. Aflibercept

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 2 small molecule completed

    1 trial

  16. Aldesleukin

    United Therapeutics Europe Ltd

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  17. Aleniglipron

    Structure Therapeutics

    Obese

    phase 2 small molecule active

    1 trial

  18. Aleniglipron or Placebo

    Structure Therapeutics

    Obesity, Overweight, or Chronic Weight Management

    phase 2 small molecule active

    2 trials

  19. Antimicrobial agent

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Ulcers (DFUs)

    phase 2 small molecule active

    1 trial

  20. BI 1815368, BI 1815368 Placebo, BI 1815368

    Boehringer Ingelheim

    Centre-involved diabetic macular edema

    phase 2 small molecule active

    1 trial

  21. BI 456906

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  22. BI 764524, Sham Injection Procedure

    Boehringer Ingelheim

    Diabetic retinopathy

    phase 2 small molecule active

    1 trial

  23. Bempedoic acid + Ezetimibe FDC Oral Tablet

    Esperion Therapeutics

    Diabetes

    phase 2 small molecule completed

    1 trial

  24. Bicifadine

    XTL BIOPHARMACEUTICALS LTD

    Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  25. Bicifadine

    XTL BIOPHARMACEUTICALS LTD

    Chronic Peripheral Neuropathy Pain in Diabetics

    phase 2 small molecule terminated

    1 trial

  26. Bisphosphocin Nu-3

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infections

    phase 2 small molecule completed

    1 trial

  27. Bivamelagon

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule active

    1 trial

  28. CF102

    Can-Fite BioPharma

    Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  29. CLBS03 Low Dose

    LISATA THERAPEUTICS, INC.

    Diabetes Mellitus

    phase 2 mab completed

    1 trial

  30. CRV431 75mg

    Hepion Pharmaceuticals

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  31. CS-3150

    Daiichi Sankyo

    Diabetic Nephropathy

    phase 2 small molecule completed

    1 trial

  32. CSG452 (Tofogliflozin) placebo, pemafibrate, K-877 ER (Pemafibrate) placebo, TOFOGLIFLOZIN

    The George Institute

    Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis

    phase 2 small molecule active

    1 trial

  33. CX11, Placebo to cx11 40 mg, CX11, Placebo to cx11 80 mg

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  34. CYCLIZINE , CALCIUM CARBONATE , Placebo for azd9550, CALCIUM CITRATE , CALCIUM GLUCONATE , Placebo for azd6234, Placebo for azd9550, AZD6234, GLUCOSE , GLUCAGON , ONDANSETRON

    AstraZeneca AB

    Investigating obesity or overweight condition correlated to many co-morbidities

    phase 2 small molecule active

    1 trial

  35. Canakinumab 150 mg

    Novartis Pharmaceuticals

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  36. Cohort A: ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    T2DM (Type 2 Diabetes Mellitus)

    phase 2 small molecule completed

    1 trial

  37. DA-302168S

    Chendu DIAO Pharmaceutical Group CO., LTD.

    Overweight and Obesity

    phase 2 small molecule active

    1 trial

  38. DCCR (diazoxide choline) extended-release tablets

    SOLENO THERAPEUTICS INC

    SH2B1 Deficiency Obesity

    phase 2 small molecule active

    1 trial

  39. DIABECELL(R)

    Otsuka Beijing Research Institute

    Type 1 Diabetes

    phase 2 other completed

    1 trial

  40. DM199

    DiaMedica Therapeutics

    Diabetes Type 2

    phase 2 small molecule completed

    1 trial

  41. Diamyd

    Wuhan Createrna Science and Technology Co., Ltd

    Latent Autoimmune Diabetes in Adults (LADA)

    phase 2 small molecule active

    1 trial

  42. EXENATIDE

    Disc Medicine

    Gestational diabetes

    phase 2 small molecule active

    1 trial

  43. EXENATIDE , VERAPAMIL

    Disc Medicine

    type 1 diabetes mellitus

    phase 2 small molecule active

    1 trial

  44. Eat Well Live Well Nutrition Program

    Grace Therapeutics

    Diabetes or Diabetes Prevention

    phase 2 other completed

    1 trial

  45. Evogliptin

    Samsung Bioepis NL B.V.

    Type2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  46. External Chinese medicine

    Universal Integrated

    Diabetic Foot

    phase 2 small molecule active

    1 trial

  47. Fasiglifam

    Takeda

    Type 2 Diabetes Mellitus

    phase 2 small molecule terminated

    2 trials

  48. G-Pen Mini™ (glucagon injection)

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

755 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.